Market News & Trends
PhaseBio Enters Worldwide License Agreement With MedImmune
PhaseBio Pharmaceuticals, Inc. recently announced it has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for…
TGR-1202 Selected as the PI3K Delta Inhibitor to be Used in Multiple-Arm Comparison Study
TG Therapeutics recently announced that along with SWOG, the global cancer clinical trials group funded by the National Cancer Institute (NCI), it has initiated a…
Vaccinex & Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development
Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag® conjugation platform and GPEx® cell…
Navitas Brings End-to-End R&D Solutions to the Generic Drug Industry
Navitas Life Sciences, a TAKE Solutions Enterprise, provides services and technology to deliver "first-to-file" results to generic drug companies around the globe, allowing them to…
G1 Therapeutics & AstraZeneca Enter Clinical Trial Collaboration
G1 Therapeutics, Inc. recently announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib)…
Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study
Aptevo Therapeutics Inc. recently announced recent developments related to the Company’s novel ADAPTIR bispecific antibody platform, including the planned commencement of a Phase 2 clinical…
Cesca Therapeutics Announces Issuance of Second Cellular Processing Patent Surrounding Company’s X-BACS Technology
Cesca Therapeutics Inc. recently announced that on November 21, 2017, the USPTO awarded the company a new US Patent No. 9,821,111 (the ‘111 patent), entitled…
Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial
Nevakar, LLC recently announced that the first subject has been dosed in a Phase 3 clinical trial of NVK-002, the company's investigational, topical ophthalmic solution…
Ablynx’s Phase III HERCULES Study Selected for Oral Presentation
Ablynx NV announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six abstracts for oral presentation…
Lead Pharma Achieves Third Milestone in Sanofi Collaboration
Lead Pharma recently announced it has achieved a third milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment. The collaboration aims to…
Immunovaccine & Leidos Expand Collaboration
Immunovaccine Inc. recently announced it is expanding its collaboration with Leidos to develop preventative, peptide-based malaria vaccine candidates. The US Agency for International Development (USAID)…
TESARO Secures $500-Million Financing
TESARO, Inc. recently announced it has entered into a definitive term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA CREDIT INVESTMENTS IV SUB LP, investment…
CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Research Programs
Crown Bioscience recently announced the publication of two new papers illustrating the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and…
Flexicare Acquires Medisize B.V.
Flexicare (Group) Limited, a leading UK headquartered manufacturer of medical devices, recently announced it has acquired Medisize B.V. from an affiliate of Phillips-Medisize, LLC. …
Quotient Sciences Acquires Pharmaterials, Launches as New Global Identity for Quotient Clinical
Quotient Sciences, the drug development services organization, recently announced it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, UK. The…
SOTIO Completes Enrolment of Phase III VIABLE Study
SOTIO, a biotechnology company owned by the PPF Group, recently announced the enrolment of the last patient into the VIABLE study, a global Phase III…
West Announces Official Opening of Expanded Kiefernweg Campus & New Center of Excellence for Innovation & Technology
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, officially opened the Company’s recently expanded Kiefernweg Campus in Eschweiler, Germany,…
SIO-ADM & Gattefossé Announce Partnership
Gattefossé USA and Gattefossé Canada recently announce their partnership with Société Industrielle des Oléagineux (SIO), a subsidiary of Archer Daniels Midland Company (ADM), to bring…
G1 Therapeutics Announces Publication in Cancer Discovery
G1 Therapeutics, Inc. recently announced the publication CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation, is available online in the journal Cancer Discovery.…
Organovo & Viscient Biosciences Collaborate to Develop Custom Research Platform
Organovo Holdings, Inc. and Viscient Biosciences recently announced a collaboration to develop a custom research platform for studying liver disease. The partnership is expected to…
